Similar articles

• Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol.

  Bayturan O, Kapadia S, Nicholls SJ, Tuzcu EM, Shao M, Uno K, Shreevatsa A, Lavoie AJ, Wolski K, Schoenhagen P, Nissen SE. Bayturan O, et al. J Am Coll Cardiol. 2010 Jun 15;55(24):2736-42. doi: 10.1016/j.jacc.2010.01.050. J Am Coll Cardiol. 2010. PMID: 20538166 Clinical Trial.
• High-dose statins and atherosclerosis regression.

  von Birgelen C, Hartmann M. von Birgelen C, et al. JAMA. 2006 Oct 18;296(15):1837; author reply 1837. doi: 10.1001/jama.296.15.1837-a. JAMA. 2006. PMID: 17047210 No abstract available.
• Halting the progression of atherosclerosis with intensive lipid lowering: results from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial.

  Nissen SE. Nissen SE. Am J Med. 2005 Dec;118 Suppl 12A:22-7. doi: 10.1016/j.amjmed.2005.09.020. Am J Med. 2005. PMID: 16356804
• [Secondary prevention of patients with ischaemic heart disease--the reduction of LDL cholesterol level and the regression of atherosclerosis].

  Bárczi G, Merkely B. Bárczi G, et al. Lege Artis Med. 2007 Oct;17(10):675-9. Lege Artis Med. 2007. PMID: 19227597 Review. Hungarian.
• Lessons from coronary intravascular ultrasound on the importance of raising high-density lipoprotein cholesterol.

  Nicholls SJ, Uno K, Tuzcu EM, Nissen SE. Nicholls SJ, et al. Curr Atheroscler Rep. 2010 Sep;12(5):301-7. doi: 10.1007/s11883-010-0125-4. Curr Atheroscler Rep. 2010. PMID: 20628836 Review.